Coventry chemotherapy scandal and serious concerns over prolonged
cancer treatment.
Coventry chemotherapy scandal and potential clinical negligence following a review by the Royal College of Physicians, the RCP has identified serious concerns about the treatment of brain tumour patients at University Hospitals Coventry and Warwickshire NHS
Trust (UHCW).
Twenty Cases Examined
The Royal College of Physicians review examined 20 cases involving patients who had received prolonged treatment with the chemotherapy drug temozolomide. Its findings raise important questions about clinical decision-making, patient safety, prescribing practices and the systems in place to monitor treatment.
What has the review found?
The findings are deeply concerning and of the 20 cases reviewed:
1. 15 were judged “unsatisfactory overall”.
2. Patients had received temozolomide for significantly longer than would normally be expected.
3. In some cases, treatment continued for years, despite little or no evidence of clinical benefit.
4. Concerns were identified about clinical decision-making and organisational governance.
5. At least one patient is reported to have received an exceptionally prolonged course of chemotherapy following a misdiagnosis.
The RCP has described the findings as a “betrayal of patient trust.”
Why is prolonged chemotherapy concerning?
Temozolomide is an established chemotherapy drug used to treat certain brain tumours. However, chemotherapy is not without risk and treatment should be based on an appropriate diagnosis, clinical evidence and regular review of whether the benefits continue to outweigh the risks.
Patients understandably accept the potential side effects of chemotherapy because they believe that the treatment is necessary to treat or control their cancer. If chemotherapy is continued when there is little or no clinical benefit, patients may potentially be exposed to unnecessary side effects and complications, as well as considerable physical and emotional distress.
The issue is therefore not simply how long chemotherapy was given, but whether there was a proper clinical justification for continuing treatment and whether the treatment was appropriately reviewed.
Were there failures in clinical governance by the trusts?
The concerns identified by the RCP appear to extend beyond individual treatment decisions. The review identified weaknesses in clinical and organisational systems, including concerns around oversight and governance of prescribing.
This raises important questions:
a. How could treatment continue for such prolonged periods without the appropriate safeguards identifying and addressing the problem?
b. Effective clinical governance should provide checks and balances around prescribing, pharmacy, clinical review and multidisciplinary decision-making.
c. Where those systems fail, patients may be placed at risk of receiving treatment that is unnecessary or inappropriate.
Could this amount to clinical negligence?
Potentially this could be clinical negligence. Whether an individual patient has a clinical negligence claim will depend upon their particular circumstances and the medical evidence.
Important questions may include:
a. Was the original diagnosis correct?
b. Was temozolomide appropriate for the patient’s particular condition?
c. How long was the treatment continued?
d. Was there a proper clinical reason for continuing it?
e. Were relevant guidelines and accepted medical practice followed?
f. Was the patient’s response to treatment properly monitored?
g. Were the risks and benefits of continued treatment properly considered and explained?
h. Were appropriate clinical governance and pharmacy checks in place?
i. Did the patient suffer injury or other loss as a result?
It is important to emphasise that the RCP review does not automatically establish legal liability in every individual case. Each claim must be considered on its own facts.
Independent medical experts may be required to establish whether the treatment fell below the appropriate standard and, importantly, whether that caused injury or other loss.
Could you or a family member be affected?
If you or someone close to you received prolonged temozolomide treatment at University Hospitals Coventry and Warwickshire, particularly if treatment continued for an unusually long period, you may wish to seek specialist legal advice.
You may wish to find out:
a. How many cycles of chemotherapy you received.
b. Why the treatment was continued.
c. What reviews took place.
d. Whether your diagnosis was subsequently questioned or changed.
e. What side effects or complications you experienced.
f. Whether the treatment has affected your health, employment, finances or quality of
life.
You do not need to know whether the treatment amounted to negligence before seeking advice. Obtaining and reviewing your medical records can be an important first step.
Time limits can apply. Clinical negligence claims are subject to strict limitation rules. The fact that concerns have only recently been reported publicly does not necessarily mean that the limitation period starts from the date of the news report.
If you are concerned that you or a family member may have been affected, it is therefore important to seek advice without unnecessary delay.
How our clinical negligence team can help.
Our specialist clinical negligence solicitors can investigate concerns about unnecessary or prolonged cancer treatment, obtain and review the relevant medical records and, where appropriate, obtain independent medical evidence. We understand that discovering that treatment you trusted may not have been necessary can be extremely distressing. Our role is to establish what happened, whether the appropriate standard of care was provided and whether you have suffered harm as a result. We offer No Win No Fee.
If you believe you or a family member may have been affected by the Coventry chemotherapy concerns, contact our clinical negligence team for a Free confidential, no-obligation discussion about your circumstances.
This article is intended for general information only and does not constitute legal advice. Every clinical negligence claim is assessed on its individual facts and medical evidence.